Redeye initiates coverage of CTEK, a market leader within premium low-voltage chargers that is lever...
Investors House announced today that it has divested its 1/3 stake in Jyväskylän Kukkulan Kehitys Oy...
We forecast 21% y-o-y ARR growth and 15% adj. EBITDA margin.
Q2e: 6% organic sales growth y-o-y, 9% adj. EBITA margin Expect a softer Q2, partly on further marke...
Redeye leaves a comment following today’s announcement of the outcome of Alzinova’s recent rights is...
Summarising an eventful H1'24 Many players in the Parkinson's therapy game.
We make minor changes to adjusted EBITA for 2024E-26E ahead of Q2.
Redeye provides a comment on the outcome in Respiratorius’ rights issue, announced earlier this afte...
Redeye comments on Truecaller ahead of its Q2 results, which are due on 19 July.
The European Medicines Agency (EMA) has approved Cereno Scientific’s Clinical Trial Application (CTA...
Clavister could provide cybersecurity to Thales' SOTAS communication system A tangible revenue case ...
Q2 report due 15 August '24e-'26e EBITA down 5-1%; 9% CAGR '23-'26e 10-6x EBITA '24e-'26e, 11-15% FC...
Redeye provides a research update on Faron Pharmaceuticals following the outcome of the company’s re...
Biovica records IVD test sales in Q4, which are higher than Q1-Q3, and research test sales have incr...
Redeye comments on the news that the company’s complementary clinical study TRIAC II, which focused ...
Redeye comments on Artificial Solutions' directed rights issue, which was announced after the market...
Niche heat pump OEM with high growth potential Return to positive margins FY'25/26e 10-5x EBIT '25e-...
Redeye comments on Verve’s acquisition of Jun Group, which strengthens its position on the demand si...
The company changed its strategy and abandons its plans to build 600MW of own wind power capacity.
CoinShares International (CS) is a pioneer and a well-established player in the nascent, high-growth...
